Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE

SHANGHAI and GAITHERSBURG, Md., Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has entered into a strategic collaborati...

2021-11-08 21:00 1611

RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill

TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a strategic agreement with Kukbo Co. Lt...

2021-11-08 20:00 2099

RadLink, Singapore's Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-rays and Mammograms

SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Lunit today announced a Reference Site Agreement with RadLink, a subsidiary of the Fullerton Health Group,Singapore's leading private diagnostic and molecular imaging service provider. As a leading medical AI company, Lunit provides AI software th...

2021-11-08 14:36 3338

RadLink, Singapore's Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-rays and Mammograms

Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases

HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announce today that Ascletis' subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license agreement ou...

2021-11-08 08:30 2409

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...

2021-11-08 08:15 2307

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...

2021-11-08 08:10 1678

Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications

SAN FRANCISCO and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...

2021-11-08 08:00 2624

Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections

BANGALORE, India; SARATOGA, Calif. and ADELAIDE, Australia, Nov. 8, 2021 /PRNewswire/ -- Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), s...

2021-11-08 07:00 5363

Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections

Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity

* The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo * The trial also showed that 77.1% of study participants who received Wegovy™ lost at least 5% of their bo...

2021-11-05 20:58 2720

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

* Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for predicting future decline in kidney function in patients with type 2 diabetes * PromarkerD correctly identified 84% of patients with normal kidney function that went on to experience kidney f...

2021-11-05 20:37 1603

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

MELBOURNE, Australia, Nov. 5, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studie...

2021-11-05 14:57 1398

CIIE 2021: Offering new opportunities for COVID recovery

SHANGHAI, Nov. 5, 2021 /PRNewswire/ -- On Nov 5, the China International Import Expo (CIIE), the first national-level import-themed professional trade fair nowadays in the world, successfully opened at the National Exhibition and Convention Center (Shanghai). Initiated by the Chinese government s...

2021-11-05 11:30 6693

CIIE 2021: Offering new opportunities for COVID recovery

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

SUZHOU, China, and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on six studies of the company's thr...

2021-11-05 09:05 3044

ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting

SUZHOU, China and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on three clinical trials of the c...

2021-11-05 08:43 2126

New Data at ASH 2021 Reinforces the Strength of Servier's Hematology Portfolio

First Phase 3 results from the AGILE trial in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation show improved event-free survival and various secondary outcomes, including complete remission, overall survival and objective response rate, with ivosidenib tablets (TIBSOVO®)...

2021-11-05 08:05 2253

Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization

All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO GAITHERSBURG, Md., Nov. 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infec...

2021-11-05 05:00 2713

Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT

SEOUL, South Korea, Nov. 4, 2021 /PRNewswire/ -- Lunit, a leading medical AI provider, will be returning to the 107th Radiological Society ofNorth America (RSNA) this year with its up-to-date, comprehensive AI solutions for chest and breast radiology. Along with its most mature products, the comp...

2021-11-04 23:00 1629

Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT

Associates of Cape Cod Inc. Announces the Release of its One Millionth Horseshoe Crab From its Species Sustainability Project

E. FALMOUTH, Mass., Nov. 4, 2021 /PRNewswire/ -- ACC proudly announces that it has achieved the release of its millionth juvenile horseshoe crab to the wild, as a result of its species sustainability project. The program is the first of its kind to release ecologically significant numbers of Nort...

2021-11-04 21:30 2320

Associates of Cape Cod Inc. Announces the Release of its One Millionth Horseshoe Crab From its Species Sustainability Project

International Federation of Robotics: "Service Robots" Hit Double Digit Growth Worldwide

FRANKFURT AM MAIN, Germany, Nov. 4, 2021 /PRNewswire/ -- The market for professional service robots reached a turnover of6.7 billion U.S. dollars worldwide (sample method) – up 12% in 2020. At the same time, turnover of new consumer service robots grew 16% to4.4 billion U.S. dollars. This is acco...

2021-11-04 21:20 7480

Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting

SUZHOU and SHANGHAI, China, and PALO ALTO, California, Nov. 4, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...

2021-11-04 21:05 1570

1 ... 319 320 321322323 324 325 ... 576